Endocrinology of the stress response

Annual Review of Physiology

Volumn 67, Issue , 2005, Pages 259-284

  Charmandari, Evangelia ^a   Tsigos, Constantine ^a   Chrousos, George ^a  

^a NONE

Author keywords

Endocrinology of stress; Stress system; Stress related disorders

Indexed keywords

ADRENALIN; ALPHA INTERMEDIN; ARGIPRESSIN; BETA ENDORPHIN; CATECHOLAMINE; CORTICOTROPIN RELEASING FACTOR; GLUCOCORTICOID; GROWTH HORMONE; NORADRENALIN; PEPTIDE HORMONE; PROOPIOMELANOCORTIN; SOMATOMEDIN;

ADAPTATION; ALCOHOLISM; ALERTNESS; AMYGDALOID NUCLEUS; ANOREXIA NERVOSA; APPETITE; AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM; CHOLINERGIC ACTIVITY; CHOLINERGIC TRANSMISSION; CUSHING DISEASE; CYTOKINE RELEASE; EATING DISORDER; ENDOCRINE DISEASE; ENDOCRINE FUNCTION; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; FEEDING BEHAVIOR; GASTROINTESTINAL TRACT FUNCTION; GROWTH DISORDER; GROWTH INHIBITION; HORMONAL REGULATION; HORMONE ACTION; HORMONE RELEASE; HORMONE STRUCTURE; HUMAN; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSULIN RESISTANCE; LIMBIC CORTEX; MALNUTRITION; MENTAL DISEASE; METABOLIC DISORDER; METABOLIC SYNDROME X; NEUROTRANSMISSION; OBSESSIVE COMPULSIVE DISORDER; PANIC; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM; PERSONALITY DISORDER; PRIORITY JOURNAL; PSYCHOSOMATIC DISORDER; REPRODUCTION; REVIEW; SHORT STATURE; SOCIAL INTERACTION; STEROIDOGENESIS; STRESS; SYMPATHETIC TONE; TASK PERFORMANCE; THERMOREGULATION; THYROID FUNCTION; WELLBEING;

ENDOCRINE GLANDS; HUMANS; STRESS;

EID: 15544368594     PISSN: 00664278     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.physiol.67.040403.120816     Document Type: Review

References (117)

1. Habib KE, Gold PW, Chrousos GP. 2001. Neuroendocrinology of stress. Endocrinol. Metab. Clin. North Am. 30:695-728
2. Chrousos GP, Gold PW. 1992. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA 267:1244-52
3. Chrousos GP. 2002. Organization and integration of the endocrine system. In Pediatric Endocrinology, ed. M Sperling, pp. 1-14. Philadelphia: Saunders
4. Calogero AE, Gallucci WT, Chrousos GP, Gold PW. 1988. Catecholamine effects upon rat hypothalamic corticotropin-releasing hormone secretion in vitro. J. Clin. Invest. 82:839-16
5. Valentine RJ, Foote SL, Aston-Jones G. 1983. Corticotropin-releasing factor activates noradrenergic neurons of the locus coeruleus. Brain Res. 270:363-67
6. Kiss A, Aguilera G. 1992. Participation of alpha 1-adrenergic receptors in the secretion of hypothalamic corticotropin-releasing hormone during stress. Neuroendocrinology 56:153-60
7. Calogero AE, Gallucci WT, Gold PW, Chrousos GP. 1988. Multiple feedback regulatory loops upon rat hypothalamic corticotropin-releasing hormone secretion. Potential clinical implications. J. Clin. Invest. 82:767-74
8. Silverman AJ, Hou-Yu A, Chen WP. 1989. Corticotropin-releasing factor synapses within the paraventricular nucleus of the hypothalamus. Neuroendocrinology 49:291-99
9. Aghajanian GK, VanderMaelen CP. 1982. Alpha 2-adrenoceptor-mediated hyperpolarization of locus coeruleus neurons: intracellular studies in vivo. Science 215:1394-96
10. Calogero AE, Bagdy G, Szemeredi K, Tartaglia ME, Gold PW, Chrousos GP. 1990. Mechanisms of serotonin receptor agonist-induced activation of the hypothalamic-pituitary-adrenal axis in the rat. Endocrinology 126:1888-94
11. Fuller RW. 1996. Serotonin receptors involved in regulation of pituitary-adrenocortical function in rats. Behav. Brain Res. 73:215-19
12. Calogero AE, Gallucci WT, Chrousos GP, Gold PW. 1988. Interaction between GABAergic neurotransmission and rat hypothalamic corticotropin-releasing hormone secretion in vitro. Brain Res. 463:28-36
13. Overton JM, Fisher LA. 1989. Modulation of central nervous system actions of corticotropin-releasing factor by dynorphin-related peptides. Brain Res. 488(1-2):233-40
14. Keller-Wood ME, Dallman MF. 1984. Corticosteroid inhibition of ACTH secretion. Endocr. Rev. 5:1-24
15. Bale TL, Vale WW. 2004. CRF and CRF receptors: role in stress responsivity and other behaviors. Annu. Rev. Pharmacol. Toxicol. 44:525-57
16. Egawa M, Yoshimatsu H, Bray GA. 1991. Neuropeptide Y suppresses sympathetic activity to interscapular brown adipose tissue in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 260:R328-34
17. Oellerich WF, Schwartz DD, Malik KU. 1994. Neuropeptide Y inhibits adrenergic transmitter release in cultured rat superior cervical ganglion cells by restricting the availability of calcium through a pertussis toxin-sensitive mechanism. Neuroscience 60:495-502
18. White BD, Dean RG, Edwards GL, Martin RJ. 1994. Type II corticosteroid receptor stimulation increases NPY gene expression in basomedial hypothalamus of rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 266:R1523-29
19. Larsen PJ, Jessop D, Patel H, Lightman SL, Chowdrey HS. 1993. Substance P inhibits the release of anterior pituitary adrenocorticotrophin via a central mechanism involving corticotrophin-releasing factor-containing neurons in the hypothalamic paraventricular nucleus. J. Neuroendocrinol. 5:99-105
20. Chrousos GP. 1992. Regulation and dysregulation of the hypothalamic-pituitary-adrenal axis: the corticotropin releasing hormone perspective. Endocrinol. Metab. Clin. North Am. 21:833-58
21. Tsigos C, Chrousos GP. 1994. Physiology of the hypothalamic-pituitary- adrenal axis in health and dysregulation in psychiatric and autoimmune disorders. Endocrinol. Metab. Clin. North Am. 23:451-66
22. Gillies GE, Linton EA, Lowry PJ. 1982. Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin. Nature 299:355-57
23. Abou-Samra AB, Harwood JP, Catt KJ, Aguilera G. 1987. Mechanisms of action of CRF and other regulators of ACTH release in pituitary corticotrophs. Ann. NY Acad. Sci. 512:67-84
24. Horrocks PM, Jones AF, Ratcliffe WA, Holder G, White A, et al. 1990. Patterns of ACTH and cortisol pulsatility over twenty-four hours in normal males and females. Clin. Endocrinol. (Oxf). 32(1):127-34
25. Iranmanesh A, Lizarralde G, Short D, Veldhuis JD. 1990. Intensive venous sampling paradigms disclose high frequency adrenocorticotropin release episodes in normal men. J. Clin. Endocrinol. Metab. 71(5):1276-83
26. Veldhuis JD, Iranmanesh A, Johnson ML, Lizarralde G. 1990. Amplitude, but not frequency, modulation of adrenocorticotropin secretory bursts gives rise to the nyctohemeral rhythm of the corticotropic axis in man. J. Clin. Endocrinol. Metab. 71:452-63
27. Calogero AE, Norton JA, Sheppard BC, Listwak SJ, Cromack DT, et al. 1992. Pulsatile activation of the hypothalamic-pituitary-adrenal axis during major surgery. Metabolism 41:839-45
28. Holmes MC, Antoni FA, Aguilera G, Catt KJ. 1986. Magnocellular axons in passage through the median eminence release vasopressin. Nature 319:326-29
29. Andreis PG, Neri G, Mazzocchi G, Musajo F, Nussdorfer GG. 1992. Direct secretagogue effect of corticotropin-releasing factor on the rat adrenal cortex: the involvement of the zona medullaris. Endocrinology 131:69-72
30. Ottenweller JE, Meier AH. 1982. Adrenal innervation may be an extrapituitary mechanism able to regulate adrenocortical rhythmicity in rats. Endocrinology 111:1334-38
31. Bornstein SR, Chrousos GP. 1999. Clinical review 104: adrenocorticotropin (ACTH)- and non-ACTH-mediated regulation of the adrenal cortex: neural and immune inputs. J. Clin. Endocrinol. Metab. 84:1729-36
32. Munck A, Guyre PM, Holbrook NJ. 1984. Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr. Rev. 5:25-44
33. Kino T, Chrousos GP. 2001. Glucocorticoid and mineralocorticoid resistance/hypersensitivity syndromes. J. Endocrinol. 169:437-45
34. Bamberger CM, Schulte HM, Chrousos GP. 1996. Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr. Rev. 17:245-61
35. Chrousos GP. 1997. The neuroendocrinology of stress: Its relation to the hormonal milieu, growth and development. Growth Genet. Horm. 13:1-8
36. Roth RH, Tam SY, Ida Y, Yang JX, Deutch AY. 1988. Stress and the mesocorticolimbic dopamine systems. Ann. NY Acad. Sci. 537:138-47
37. Imperato A, Puglisi-Allegra S, Casolini P, Angelucci L. 1991. Changes in brain dopamine and acetylcholine release during and following stress are independent of the pituitary-adrenocortical axis. Brain Res. 538:111-17
38. Diorio D, Viau V, Meaney MJ. 1993. The role of the medial prefrontal cortex (cingulate gyrus) in the regulation of hypothalamic-pituitary-adrenal responses to stress. J. Neurosci. 13:3839-47
39. Gray TS. 1989. Amygdala: role in autonomic and neuroendocrine responses to stress. In Stress, Neuropeptides and Systemic Disease, ed. JA McCubbin, PG Kaufman, CB Nemeroff, p. 37. New York: Academic
40. Nikolarakis KE, Almeida OF, Herz A. 1986. Stimulation of hypothalamic beta-endorphin and dynorphin release by corticotropin-releasing factor in vitro. Brain Res. 399:152-55
41. Diamant M, de Wied D. 1991. Autonomic and behavioral effects of centrally administered corticotropin-releasing factor in rats. Endocrinology 129:446-54
42. Mora F, Lee TF, Myers RD. 1983. Involvement of alpha- and beta-adrenoreceptors in the central action of norepinephrine on temperature, metabolism, heart and respiratory rates of the conscious primate. Brain Res. Bull. 11:613-16
43. Liu JP, Clarke IJ, Funder JW, Engler D. 1994. Studies of the secretion of corticotropin-releasing factor and arginine vasopressin into the hypophysealportal circulation of the conscious sheep. II. The central noradrenergic and neuropeptide Y pathways cause immediate and prolonged hypothalamic-pituitary-adrenal activation. Potential involvement in the pseudo-Cushing's syndrome of endogenous depression and anorexia nervosa. J. Clin. Invest. 93:1439-50
44. Egawa M, Yoshimatsu H, Bray GA. 1991. Neuropeptide Y suppresses sympathetic activity to interscapular brown adipose tissue in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 260:R328-34
45. Rahmouni K, Haynes WG. 2001. Leptin signaling pathways in the central nervous system: interactions between neuropeptide Y and melanocortins. BioEssays 23:1095-99
46. Raposinho PD, Pierroz DD, Broqua P, White RB, Pedrazzini T, Aubert ML. 2001. Chronic administration of neuropeptide Y into the lateral ventricle of C57BL/6J male mice produces an obesity syndrome including hyperphagia, hyperleptinemia, insulin resistance, and hypogonadism. Mol. Cell. Endocrinol. 185:195-204
47. Burguera B, Muruais C, Penalva A, Dieguez C, Casanueva FF. 1990. Dual and selective actions of glucocorticoids upon basal and stimulated growth hormone release in man. Neuroendocrinology 51:51-58
48. Magiakou MA, Mastorakos G, Gomez MT, Rose SR, Chrousos GP. 1994. Suppressed spontaneous and stimulated growth hormone secretion in patients with Cushing's disease before and after surgical cure. J. Clin. Endocrinol. Metab. 78(1):131-37
49. Magiakou MA, Mastorakos G, Chrousos GP. 1994. Final stature in patients with endogenous Cushing's syndrome. J. Clin. Endocrinol. Metab. 79:1082-85
50. Bamberger CM, Schulte HM, Chrousos GP. 1996. Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr. Rev. 17:245-61
51. Vottero A, Kimchi-Sarfaty C, Kratzsch J, Chrousos GP, Hochberg Z. 2003. Transcriptional and translational regulation of the splicing isoforms of the growth hormone receptor by glucocorticoids. Horm. Metab. Res. 35:7-12
52. Raza J, Massoud AF, Hindmarsh PC, Robinson IC, Brook CG. 1998. Direct effects of corticotrophin-releasing hormone on stimulated growth hormone secretion. Clin. Endocrinol. 48:217-22
53. Uhde TW, Tancer ME, Rubinow DR, Roscow DB, Boulenger JP, et al. 1992. Evidence for hypothalamo-growth hormone dysfunction in panic disorder: profile of growth hormone (GH) responses to clonidine, yohimbine, caffeine, glucose, GRF and TRH in panic disorder patients versus healthy volunteers. Neuropsychopharmacology 6:101-18
54. Abelson JL, Glitz D, Cameron OG, Lee MA, Bronzo M, Curtis GC. 1991. Blunted growth hormone response to clonidine in patients with generalized anxiety disorder. Arch. Gen. Psychiatry 48:157-62
55. Rodgers BD, Lau AO, Nicoll CS. 1994. Hypophysectomy or adrenalectomy of rats with insulin-dependent diabetes mellitus partially restores their responsiveness to growth hormone. Proc. Soc. Exp. Biol. Med. 207:220-26
56. Skuse D, Albanese A, Stanhope R, Gilmour J, Voss L. 1996. A new stress-related syndrome of growth failure and hyperphagia in children, associated with reversibility of growth-hormone insufficiency. Lancet 348:353-58
57. Albanese A, Hamill G, Jones J, Skuse D, Matthews DR, Stanhope R. 1994. Reversibility of physiological growth hormone secretion in children with psychosocial dwarfism. Clin. Endocrinol. 40:687-92
58. Chrousos GP, Gold PW. 1999. The inhibited child syndrome. In Origins, Biological Mechanisms and Clinical Outcomes, ed. LA Schmidt, J Schulkin, pp. 193-200. New York: Oxford Univ. Press
59. a. Chrousos GP. 1997. The future of pediatric and adolescent endocrinology. Ann. NY Acad. Sci. 816:4-8
60. Benker G, Raida M, Olbricht T, Wagner R, Reinhardt W, Reinwein D. 1990. TSH secretion in Cushing's syndrome: relation to glucocorticoid excess, diabetes, goitre, and the 'sick euthyroid syndrome'. Clin. Endocrinol. 33:777-86
61. Rivier C, Rivier J, Vale W. 1986. Stress-induced inhibition of reproductive functions: role of endogenous corticotropin-releasing factor. Science 231:607-9
62. Vamvakopoulos NC, Chrousos GP. 1994. Hormonal regulation of human corticotropin-releasing hormone gene expression: implications for the stress response and immune/inflammatory reaction. Endocr. Rev. 15:409-20
63. Chrousos GP, Torpy DJ, Gold PW. 1998. Interactions between the hypothalamic-pituitary-adrenal axis and the female reproductive system: clinical implications. Ann. Intern. Med. 129:229-40
64. MacAdams MR, White RH, Chipps BE. 1986. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann. Intern. Med. 104:648-51
65. Pau KY, Spies HG. 1997. Neuroendocrine signals in the regulation of gonadotropin-releasing hormone secretion. Chin. J. Physiol. 40:181-96
66. Luger A, Deuster PA, Kyle SB, Gallucci WT, Montgomery LC, et al. 1987. Acute hypothalamic-pituitary-adrenal responses to the stress of treadmill exercise. Physiologic adaptations to physical training. N. Engl. J. Med. 316:1309-15
67. MacConnie SE, Barkan A, Lampman RM, Schork MA, Beitins IZ. 1986. Decreased hypothalamic gonadotropin-releasing hormone secretion in male marathon runners. N. Engl. J. Med. 315:411-17
68. Vamvakopoulos NC, Chrousos GP. 1993. Evidence of direct estrogenic regulation of human corticotropin-releasing hormone gene expression. Potential implications for the sexual dimophism of the stress response and immune/ inflammatory reaction. J. Clin. Invest. 92:1896-902
69. Gold PW, Loriaux DL, Roy A, Kling MA, Calabrese JR, et al. 1986. Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications. N. Engl. J. Med. 314:1329-35
70. Pasquali R, Cantobelli S, Casimirri F, Capelli M, Bortoluzzi L, et al. 1993. The hypothalamic-pituitary-adrenal axis in obese women with different patterns of body fat distribution. J. Clin. Endocrinol. Metab. 77:341-46
71. Chrousos GP. 2000. The role of stress and the hypothalamic-pituitary- adrenal axis in the pathogenesis of the metabolic syndrome: neuro-endocrine and target tissue-related causes. Int. J. Obes. Relat. Metab. Disord. 249(Suppl.)2:S50-55
72. Roy MS, Roy A, Gallucci WT, Collier B, Young K, et al. 1993. The ovine corticotropin-releasing hormone-stimulation test in type I diabetic patients and controls: suggestion of mild chronic hypercortisolism. Metabolism 42:696-700
73. Gold PW, Chrousos GP. 2002. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol. Psychiatry 7:254-75
74. Tsigos C, Young RJ, White A. 1993. Diabetic neuropathy is associated with increased activity of the hypothalamic-pituitary-adrenal axis. J. Clin. Endocrinol. Metab. 76:554-58
75. Michelson D, Stratakis C, Hill L, Reynolds J, Galliven E. 1996. Bone mineral density in women with depression. N. Engl. J. Med. 335:1176-81
76. Tache Y, Monnikes H, Bonaz B, Rivier J. 1993. Role of CRF in stress-related alterations of gastric and colonic motor function. Ann. NY Acad. Sci. 697:233-43
77. Habib KE, Weld KP, Rice KC, Pushkas J, Champoux M, et al. 2000. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc. Natl. Acad. Sci. USA 97:6079-84
78. Suto G, Kiraly A, Tache Y. 1994. Interleukin 1 beta inhibits gastric emptying in rats: mediation through prostaglandin and corticotropin-releasing factor. Gastroenterology 106:1568-75
79. Heim C, Newport DJ, Heit S, Graham YP, Wilcox M, et al. 2000. Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. JAMA 284:592-97
80. Drossman DA, Leserman J, Nachman G, Li ZM, Gluck H, et al. 1990. Sexual and physical abuse in women with functional or organic gastrointestinal disorders. Ann. Intern. Med. 113:828-33
81. Chrousos GP. 1995. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N. Engl. J. Med. 332:1351-62
82. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. 1993. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann. Intern. Med. 119:1198-208
83. DeRijk R, Michelson D, Karp B, Petrides J, Galliven E, et al. 1997. Exercise and circadian rhythm-induced variations in plasma cortisol differentially regulate interleukin-1 beta (IL-1 beta), IL-6, and tumor necrosis factor-alpha (TNF alpha) production in humans: high sensitivity of TNF alpha and resistance of IL-6. J. Clin. Endocrinol. Metab. 82:2182-91
84. Van Gool J, van Vugt H, Helle M, Aarden LA. 1990. The relation among stress, adrenalin, interleukin 6 and acute phase proteins in the rat. Clin. Immunol. Immunopathol. 57:200-10
85. Mastorakos G, Weber JS, Magiakou MA, Gunn H, Chrousos GP. 1994. Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. J. Clin. Endocrinol. Metab. 79:934-39
86. Mastorakos G, Chrousos GP, Weber JS. 1993. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J. Clin. Endocrinol. Metab. 77:1690-94
87. Elenkov IJ, Papanicolaou DA, Wilder RL, Chrousos GP. 1996. Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production: clinical implications. Proc. Assoc. Am. Phys. 108:374-81
88. Elenkov IJ, Chrousos GP. 1999. Stress hormones, Th1/Th2 patterns, pro/anti-inflammatory cytokines and susceptibility to disease. Trends Endocrinol. Metab. 10:359-68
89. Gold PW, Goodwin FK, Chrousos GP. 1988. Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress (1). N. Engl. J. Med. 319:348-53
90. Gold PW, Goodwin FK, Chrousos GP. 1988. Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress (2). N. Engl. J. Med. 319:413-20
91. Wong ML, Kling MA, Munson PJ, Listwak S, Licinio J, et al. 2000. Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc. Natl. Acad. Sci. USA 97:325-30
92. De Bellis MD, Chrousos GP, Dorn LD, Burke L, Helmers K, et al. 1994. Hypothalamic-pituitary-adrenal axis dysregulation in sexually abused girls. J. Clin. Endocrinol. Metab. 78:249-55
93. De Bellis MD, Lefter L, Trickett PA, Putnam FW Jr. 1994. Urinary catecholamine excretion in sexually abused girls. J. Am. Acad. Child Adolesc. Psychiatry 33:320-27
94. Kaye WH, Gwirtsman HE, George DT, Ebert MH, Jimerson DC, et al. 1987. Elevated cerebrospinal fluid levels of immunoreactive corticotropin-releasing hormone in anorexia nervosa: relation to state of nutrition, adrenal function, and intensity of depression. J. Clin. Endocrinol. Metab. 64:203-8
95. Malozowski S, Muzzo S, Burrows R, Leiva L, Loriaux L, et al. 1990. The hypothalamic-pituitary-adrenal axis in infantile malnutrition. Clin. Endocrinol. 32:461-65
96. Gold PW, Pigott TA, Kling MA, Kalogeras K, Chrousos GP. 1988. Basic and clinical studies with corticotropin-releasing hormone. Implications for a possible role in panic disorder. Psychiatr. Clin. North Am. 11:327-34
97. Wand GS, Dobs AS. 1991. Alterations in the hypothalamic-pituitary-adrenal axis in actively drinking alcoholics. J. Clin. Endocrinol. Metab. 72:1290-95
98. Von Bardeleben U, Heuser I, Holsboer F. 1989. Human CRH stimulation response during acute withdrawal and after medium-term abstention from alcohol abuse. Psychoneuroendocrinology 14:441-49
99. Jeanrenaud B, Rohner-Jeanrenaud F. 2000. CNS-periphery relationships and body weight homeostasis: influence of the glucocorticoid status. Int. J. Obes. Relat. Metab. Disord. (Suppl.)2:S74-76
100. Pacak K, McCarty R, Palkovits M, Cizza G, Kopin IJ, et al. 1995. Decreased central and peripheral catecholaminergic activation in obese Zucker rats. Endocrinology 136:4360-67
101. Ehlert U, Gaab J, Heinrichs M. 2001. Psychoneuroendocrinological contributions to the etiology of depression, posttraumatic stress disorder, and stress-related bodily disorders: the role of the hypothalamus-pituitary-adrenal axis. Biol. Psychol. 57:141-52
102. Demitrack MA, Crofford LJ. 1998. Evidence for and pathophysiologic implications of hypothalamic-pituitary-adrenal axis dysregulation in fibromyalgia and chronic fatigue syndrome. Ann. NY Acad. Sci. 840:684-97
103. Puddey IB, Vandongen R, Beilin LJ, English D. 1984. Haemodynamic and neuroendocrine consequences of stopping smoking - a controlled study. Clin. Exp. Pharmacol. Physiol. 11:423-26
104. Gomez MT, Magiakou MA, Mastorakos G, Chrousos GP. 1993 The pituitary corticotroph is not the rate-limiting step in the postoperative recovery of the hypothalamic-pituitary-adrenal axis in patients with Cushing syndrome. J. Clin. Endocrinol. Metab. 77:173-77
105. Sternberg EM, Hill JM, Chrousos GP, Kamilaris T, Listwak SJ, et al. 1989. Inflammatory mediator-induced hypothalamic-pituitary-adrenal axis activation is defective in streptococcal cell wall arthritis-susceptible Lewis rats. Proc. Natl. Acad. Sci. USA 86:2374-78
106. Petrich J, Holmes TH. 1977. Life change and onset of illness. Med. Clin. North Am. 61:825-38
107. Chikanza IC, Petrou P, Kingsley G, Chrousos G, Panayi GS. 1992. Defective hypothalamic response to immune and inflammatory stimuli in patients with rheumatoid arthritis. Arthritis Rheum. 35:1281-88
108. Magiakou MA, Mastorakos G, Rabin D, Dubbert B, Gold PW, Chrousos GP. 1996. Hypothalamic corticotropin-releasing hormone suppression during the postpartum period: implications for the increase in psychiatric manifestations at this time. J. Clin. Endocrinol. Metab. 81:1912-17
109. Elenkov IJ, Wilder RL, Bakalov VK, Link AA, Dimitrov MA, et al. 2001. IL-12, TNF-alpha, and hormonal changes during late pregnancy and early postpartum: implications for autoimmune disease activity. J. Clin. Endocrinol. Metab. 86:4933-38
110. Plomin R, Owen MJ, McGuffin P. 1994. The genetic basis of complex human behaviors. Science 264:1733-39
111. Bouchard TJ Jr. 1994. Genes, environment, and personality. Science 264:1700-1
112. Suomi SJ. 1991. Early stress and adult emotional reactivity in rhesus monkeys. Ciba Found Symp. 156:171-83; discussion 183-88
113. Goland RS, Jozak S, Warren WB, Conwell IM, Stark RI, Tropper PJ. 1993. Elevated levels of umbilical cord plasma corticotropin-releasing hormone in growth-retarded fetuses. J. Clin. Endocrinol. Metab. 77:1174-79
114. Webster EL, Lewis DB, Torpy DJ, Zachman EK, Rice KC, Chrousos GP. 1996. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 137:5747-50
115. Bornstein SR, Webster EL, Torpy DJ, Richman SJ, Mitsiades N, et al. 1998. Chronic effects of a nonpeptide corticotropin-releasing hormone type I receptor antagonist on pituitary-adrenal function, body weight, and metabolic regulation. Endocrinology 139:1546-55
116. Habib KE, Weld KP, Rice KC, Pushkas J, Champoux M, et al. 2000. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc. Natl. Acad. Sci. USA 97:6079-84
117. Grammatopoulos DK, Chrousos GP. 2002. Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists. Trends Endocrinol. Metab. 13:436-44